Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Burkitt Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Biphenotypic, Acute 2Oropharyngeal Neoplasms 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Cranial Nerve Diseases 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1

Interventions

Cyclophosphamide 62Rituximab 52fludarabine 34Prednisone 34Doxorubicin 29Vincristine 26Biopsy 26Specimen Handling 22Magnetic Resonance Spectroscopy 20Bendamustine Hydrochloride 19pembrolizumab 17Lenalidomide 17obinutuzumab 14fludarabine phosphate 14Etoposide 14venetoclax 13Tacrolimus 11Mycophenolic Acid 10Melphalan 10Dexamethasone 10zanubrutinib 9ibrutinib 9acalabrutinib 9Radiotherapy 9Gemcitabine 9Cytarabine 9Busulfan 9Whole-Body Irradiation 8Mesna 8Filgrastim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Medrol Veriderm × 1 year × Clear all
NCT07072585 2025-12-31

Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

Children's Oncology Group

Phase 2/3 Not yet recruiting
1,708 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡